Briefing
The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial.
A tumor-informed approach was feasible (first draw at a median of 5 weeks). 40% were ctDNA-positive after resection, independent of usual clinicopathologic risk factors. Of 54 ctDNA-negative patients, 24 (44%) were de-escalated to a planned 3 months of adjuvant chemotherapy. Median RFS was 13 months if ctDNA-positive vs 22 months if negative (HR 0.52, P=0.003).
- n: 102 enrolled; 40 ctDNA-positive, 54 negative, 4 ineligible (no tumor mutation); median follow-up 36 months
- Assay: tumor-informed (brand not named in the extracted results)